📢 AbbVie is set to acquire University of Pennsylvania’s spinout, Capstan Therapeutics for up to $2.1 billion in cash, representing one of the major acquisitions in the CGT space in 2025. ⭐ The acquisition price represents a significant premium over Capstan's last valuation, however, with this deal AbbVie gains full access to Capstan's key programs and most importantly its proprietary in vivo cell engineering technology, which was developed by the world-renowned scientists. ⭐